Dision Medical Secures Tens of Millions in Series A Funding to Accelerate Domestic Substitution of Meibomian Gland Dysfunction Therapeutic Devices and Development of Intelligent Corneal Cross-Linking Systems

VCBeat learned exclusively that DisionTech (Shenzhen DisionTech Biomedical Technology Co., Ltd.) announced the completion ofShenzhen Guochuang Qinzhi Angel FundAndAutek ChinaTens of millions of yuan in Series A round funding. This round of financing will be mainly used for the clinical trials of the intelligent corneal cross-linking instrument and the sales promotion of the meibomian gland treatment device.

DisionTech Focuses on Innovation in Ophthalmic Equipment, Aiming for the Domestic Substitution of High-End Ophthalmic Medical Devices in China. Its Product Lines Cover Multiple Areas Such as Dry Eye Syndrome, Vision Correction, and Ocular Surgery. The Company's R&D is Supported by the Shenzhen Bio-Manufacturing Technology and Application Engineering Laboratory at Tsinghua University's Shenzhen International Graduate School. It Has Completed the Development and Integration of the Entire Supply Chain for Meibomian Gland Treatment Devices and Intelligent Corneal Cross-Linking Instruments. Currently, DisionTech is Actively Working on the R&D of Next-Generation Meibomian Gland Treatment Devices, Home-Use Dry Eye Treatment Equipment, and High-End Anterior Segment OCTs Related to Ophthalmology.

In April 2024, DisionTech's self-developed intelligent visualized meibomian gland treatment device, DisionEyemore (Guangdong Medical Device Registration Certificate No. 20242160609), obtained the first certificate for a domestically produced meibomian gland treatment device in China. It successfully obtained the production license in June and achieved its first sale at an independent private hospital in the Guangdong-Hong Kong-Macao Greater Bay Area in the same month.

Intelligent Visualized Meibomian Gland Treatment Device DisionEyemore

DisionEyemore Intelligent Visualized Meibomian Gland Treatment Device innovatively adopts "electric heating," integrating advanced thermal pulsation technology with a high-precision visualization system. During the treatment process, it heats both the upper and lower meibomian glands to an optimal therapeutic temperature of 40-42.5°C, rapidly softening meibum. The heating range reaches 17.18mm, and a single eyelid treatment takes only 2-3 minutes to effectively unclog and restore meibomian gland function. Patients experience only a warm sensation during the procedure, which is completely non-invasive and pain-free.

The main unit of the therapy device is equipped with a 1.5-inch RGB color screen and a camera function, which not only displays temperature and pressure in real time to assist doctors in developing personalized treatment plans and evaluating treatment effects on the spot, but also records the entire treatment process for doctors to track treatment efficacy. Additionally, it allows intuitive presentation of treatment outcomes to patients, overcoming the limitation of similar products that can only be observed through a magnifying glass without the ability to take photos for record-keeping.

As of now, the intelligent visual meibomian gland treatment device DisionEyemore has been introduced into Aier Eye Hospital Group. At the same time, trial use and sales work have been carried out with dozens of public hospitals and ophthalmology groups across China, successfully selling dozens of units, with sales exceeding one million yuan.

The Intelligent Corneal Cross-Linking Device is another key product from DisionTech. Specifically designed for corneal conditions such as keratoconus, it enhances the biomechanical strength of the cornea through a specialized cross-linking technology, slowing or halting disease progression and improving cornea-related symptoms.

Keratoconus (KC) commonly occurs during puberty and is a prevalent bilateral expansion disease that is often asymmetric. It is characterized by corneal expansion, with the central or paracentral area thinning and protruding forward in a conical shape. As the condition progresses, keratoconus can lead to progressive myopia, irregular astigmatism, and corneal scarring, causing significant vision loss in advanced stages and potentially leading to blindness. Currently, the number of keratoconus patients in China is approximately 6 to 12 million, with an earlier onset age and faster progression.^[1], and is therefore known as the "invisible killer" of adolescent vision.

Image provided by DisionTech

In the late stage of keratoconus, the only treatment available is corneal transplantation. However, due to the extreme scarcity of corneal donors in China and the high cost of surgery, countless patients with keratoconus can only endure their blurred world.

Corneal cross-linking is currently the clinically recognized mainstream treatment to delay the progression of keratoconus, aiming to avoid progression to corneal transplantation.

Due to the need for high-precision light energy adjustment and monitoring technology, and the requirement to accurately control light energy within an appropriate range under complex conditions such as different corneal thicknesses, varying degrees of lesions, and individual differences, the technical threshold is quite high. The current market is mainly dominated by foreign manufacturers such as Italian company iromed (cf x-linker corneal cross-linking device) and American company Avedro (Avedro corneal cross-linking device).

To break the foreign monopoly, DisionTech is vigorously advancing the development of an intelligent corneal cross-linking device and has completed the production of the first-generation prototype, cumulatively obtaining nearly ten related invention patents.It is reported that the intelligent corneal cross-linking instrument can achieve intelligent energy distribution control, precisely adjust light intensity, spot size, irradiation distance, etc., to meet personalized treatment needs. The multi-axis联动 optical center it carries supports an eye-tracking system, enhancing operational convenience. Additionally, with its intelligent human-computer interaction system, it can analyze doctors' surgical habits and characteristics, enabling more intelligent operation.

For the acquisition of this round of financing,DisionTech Team Stated: This round of financing has brought in industrial investors such as the Guochuang Qinzhi Fund and Autek China Investment Fund, accelerating the marketization of innovative products developed by DisionTech. Amidst the wave of innovation in ophthalmic healthcare, DisionTech has consistently adhered to its mission of "Empowering health through technology, safeguarding vision through innovation," striving to break the monopoly of imported products and promote the popularization and upgrading of high-end domestically produced ophthalmic equipment. We believe that through our efforts, we can bring greater value to the global ophthalmic healthcare industry and improve the quality of life for patients! We deeply understand that every technological breakthrough and the realization of clinical value cannot be achieved without like-minded partners walking alongside us.

If you are an explorer in the field of ophthalmic R&D, we welcome you to join our innovative team. Relying on top-tier research platforms such as Tsinghua University, we will work together to overcome technical challenges and transform laboratory inspirations into products that change patients' lives. If you are a visionary in the capital market, we sincerely invite you to stand shoulder-to-shoulder with industry partners like Guochuang Qinzhi and Autek China, sharing the trillion-dollar blue ocean opportunity of domestic substitution in ophthalmic medical devices. If you are a pioneer in the medical market, we look forward to deepening our cooperation with you, accelerating product implementation, and enabling more patients to benefit from DisionTech's cutting-edge technology. The future of ophthalmic healthcare requires the wisdom and strength of more people. DisionTech is willing to stand side by side with you, using innovation as the pen and responsibility as the ink, to jointly write a new chapter in the rise of China’s ophthalmic device industry! Let us join hands to make a clear vision within reach!

Wei Qingtian, Investment Director of Guochuang ZhiyuanDisionTech, as an original innovation target in China's domestically produced ophthalmic devices, adheres to a dual-driven approach of clinical orientation and market orientation in product development. The company focuses on the premium track of consumer ophthalmology with its product portfolio. The intelligent visual meibomian gland massager and the intelligent patterned corneal cross-linking device can cover the markets for refractive errors and dry eye syndrome, which have the largest patient populations in China. With substantial technical reserves and broad overall market potential, domestically produced ophthalmic medical devices have long been monopolized by imported products. Promoting original innovative devices is an essential step to breaking the import monopoly, making it worthy of capital attention and investment. Guochuang Qinzhi Fund is honored to participate in this round of investment and looks forward to collaborating with the DisionTech team to advance the successive launches of innovative products, providing better clinical solutions and delivering improved therapeutic benefits to patients.

Autek China Investment Director Tang TingAutek China’s overall strategy focuses on full optometry products and all-age optometry services, with key attention on dry eye, refractive optometry examination, treatment devices, and consumables. DisionTech's core product pipeline is precisely built around these areas. Backed by Tsinghua University and leading domestic ophthalmology hospitals, the team demonstrates strong clinical demand insight and rapid engineering transformation capabilities. Its handheld thermal pulsation meibomian gland treatment device has obtained the first registration certificate for a domestically produced device in China and has reached a strategic cooperation agreement with leading domestic medical service groups, showing promising commercialization potential. The corneal cross-linking instrument has also passed type inspection and is expected to obtain the first registration certificate in China. This product is mainly used in keratoconus treatment and post-refractive surgery reinforcement and has the potential for non-invasive refractive surgery. Autek China looks forward to deepening cooperation with DisionTech in new technologies and products to provide more high-quality products and services for everyone to "see clearly and see well."

The Angel Investment Fund for the Great Health Industry of Guochuang Qinzhi was jointly initiated by Guochuang Zhiyuan, the capital operation platform under the National Innovation Center for High-Performance Medical Devices (hereinafter referred to as "Guochuang Center"), and Qinzhi Capital. The fund relies on the advanced technical advantages and national platform advantages of the Guochuang Center in the high-end medical device field and leverages the professional investment capabilities of Qinzhi Capital to focus on investment in the healthcare sector. It aims to打通 innovation, industry, and capital chains, incubate and cultivate the next generation of "unicorns" in the healthcare field, and enhance the global competitiveness of China's healthcare industry.

Autek China is the first listed company in China specializing in eye health products. Its orthokeratology lens products hold the largest market share in China. Moreover, the company has significant investments in the medical services sector, controlling approximately 500 optometry centers and ophthalmology clinics, as well as 30 ophthalmology hospitals. The company conducts external investments through its own funds and fund methods, participating in the establishment of an industrial investment fund with a total scale of nearly 1 billion yuan. Autek China’s investments rely on the listed company's industry chain to comprehensively empower invested enterprises. It aims to address unmet clinical needs within the medical industry and cultivate new benchmarks in the healthcare field.

Recommended Reading:"The First Meibomian Gland Treatment Device Made in China Approved: 430 Million People Suffering from Dry Eye Syndrome Have a New Option"

References: [1]《Whole-exome sequencing screening for candidate genes and variants associated with primary sporadic keratoconus in Chinese patients 》，Experimental Eye Research